Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Sees Significant Decline in Short Interest

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) saw a large drop in short interest in the month of November. As of November 15th, there was short interest totalling 55,000 shares, a drop of 15.4% from the October 31st total of 65,000 shares. Currently, 3.9% of the shares of the company are short sold. Based on an average trading volume of 323,700 shares, the days-to-cover ratio is currently 0.2 days.

Salarius Pharmaceuticals Stock Down 1.4 %

Shares of NASDAQ:SLRX opened at $1.43 on Monday. Salarius Pharmaceuticals has a fifty-two week low of $1.26 and a fifty-two week high of $7.27. The firm’s 50-day simple moving average is $1.53 and its 200-day simple moving average is $2.16. The company has a market cap of $2.06 million, a price-to-earnings ratio of -0.18 and a beta of 0.93.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.